RESEARCH TRIANGLE PARK, N.C., March 1, 2011 /PRNewswire/ -- Max Neeman International has established a team of experts specialized in carrying out rare disease trials in response to sponsor demand. The team has the required expertise to develop innovative approaches to optimize complex study design. Often strict inclusion/exclusion criteria and data analysis for rare disease studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.
Max Neeman is a leading CRO in India that has a focus on Rare Disease Studies, in addition to other indications. Patient enrollment for rare disease, complex global and multi-centric trials is challenging because potential subjects are fewer in number and widely dispersed. India has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment supported by the country's diverse gene pool and vast population of 1.3B.
Rare diseases are frequently life-threatening or chronically debilitating. However, drug development for these conditions has been limited by relative unavailability of subjects for clinical trials, as well as the high cost of investing in a novel pharmaceutical agent with poor market potential.
Max Neeman International conducts India-based clinical research services for clients across the globe delivering quality results and exceptional customer service at a lower cost resulting in high client satisfaction.
About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutr